Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer by Deng, Junli et al.
Deng, Junli, Wang, Li, Chen, Hongmin, Hao, Jingli, Ni, Jie, Chang, Lei, Duan, Wei, Graham, Peter and Li, 
Yong 2016, Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant 
ovarian cancer, Oncotarget, vol. 7, no. 34, pp. 55771-55788. 
DOI: 10.18632/oncotarget.9908 
This is the published version. 
©2016, Impact Journals
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
Available from Deakin Research Online: 
http://hdl.handle.net/10536/DRO/DU:30085984 
Oncotarget55771www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 34
Targeting epithelial-mesenchymal transition and cancer stem 
cells for chemoresistant ovarian cancer
Junli Deng1,2,3,4, Li Wang3,4 , Hongmin Chen3,4, Jingli Hao1,2, Jie Ni1,2, Lei Chang1,2, 
Wei Duan5, Peter Graham1,2 and Yong Li1,2
1 Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia
2 St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW, Australia
3 Department of Gynecological Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China
4 Zhengzhou University, Zhengzhou, Henan, China
5 School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia
Correspondence to: Yong Li, email: y.li@unsw.edu.au
Keywords: ovarian cancer, EMT, CSC, chemoresistance, metastasis, therapy
Received: February 11, 2016 Accepted: May 30, 2016 Published: June 07, 2016
AbstrAct
Chemoresistance is the main challenge for the recurrent ovarian cancer therapy 
and responsible for treatment failure and unfavorable clinical outcome. Understanding 
mechanisms of chemoresistance in ovarian cancer would help to predict disease 
progression, develop new therapies and personalize systemic therapy. In the last 
decade, accumulating evidence demonstrates that epithelial-mesenchymal transition 
and cancer stem cells play important roles in ovarian cancer chemoresistance and 
metastasis. Treatment of epithelial-mesenchymal transition and cancer stem cells 
holds promise for improving current ovarian cancer therapies and prolonging the 
survival of recurrent ovarian cancer patients in the future. In this review, we focus on 
the role of epithelial-mesenchymal transition and cancer stem cells in ovarian cancer 
chemoresistance and explore the therapeutic implications for developing epithelial-
mesenchymal transition and cancer stem cells associated therapies for future ovarian 
cancer treatment.
IntroductIon
 Ovarian cancer (OC) is the leading cause of 
mortality from cancers of female reproductive tract in 
the world. Epithelial ovarian cancer (EOC) accounts for 
nearly 90% of all ovarian malignant diseases. EOCs fall 
into four main subtypes: serous, mucinous, endometrioid, 
and clear cell. In 2012, OC accounted for 151,900 deaths 
worldwide and there were 238,700 patients diagnosed with 
OC, according to the latest GLOBOCAN estimates [1]. 
OC is highly curable at stage I when it is confined to the 
ovaries, with an expected 5-year survival rate of 89% [2]. 
However, due to the absence of specific symptoms and the 
lack of an effective screening strategy, approximately 75% 
of women present at an advanced stage disease, where the 
cancer has spread within peritoneal cavity and the overall 
survival (OS) rates are only 17-36% [2].
 For the early stage OC patients, surgery can 
completely remove tumor and then give patients a 
full recovery. For the advanced stage OC patients, 
cytoreductive surgery followed by platinum/taxane acts as 
a standard therapy, resulting in a 75% high initial response 
rate [3]. Although some patients may represent repeatedly 
sensitive to platinum, most patients will ultimately develop 
tumor recurrence and succumb to chemoresistant disease. 
Thus, improved targeting therapies and chemosensitization 
strategies are essential for reducing the mortality of this 
devastating malignancy. 
 Chemoresistance in cancer chemotherapy is a 
complicated process and affected by many factors. 
Although the exact mechanisms of OC chemoresistance 
and metastasis are still unclear, accumulating evidence 
supports that epithelial-mesenchymal transition (EMT) 
and cancer stem cells (CSCs) play critical roles in the 
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development of resistance to chemotherapy, tumor relapse 
and metastasis of OC patients [4-7]. Understanding 
the mechanisms of chemoresistance will help develop 
novel therapies to improve OC patients’ survival. In 
this review, we focus on the roles of EMT and CSCs in 
OC chemoresistance, and explore the EMT/CSC-based 
therapies for future OC treatment.
EMt In ovArIAn cAncEr 
chEMorEsIstAncE
EMt in oc metastasis
 EMT is a process by which epithelial cells assume 
mesenchymal characteristics, facilitating migration 
through the extracellular matrix and settlement in areas 
of new organ formation during embryogenesis. This 
cell switch is known to be integral in development, 
wound healing and stem cell behavior, and contributes 
pathologically to fibrosis and cancer progression [8]. 
EMT occurs through down-regulation of E-cadherin, 
Cytokeratins, ZO-1, Claudins, Occludin, Laminin-1, 
Entactin, MUC-1, and the microRNA (miR-200 family), 
and up-regulation of the transcription factors Snail1, 
Snail2, Twist, Zeb1 and Zeb2/SIP1, E47, KLF8, E2.2, 
Goosecoid, LEF-1, and FoxC2, as well as N-cadherin, 
Vimentin, Fibronectin, miR-10b, and miR-21 [9-11]. In 
addition, EMT was reported to be induced by multiple 
signals, including growth factors, the Wnt/β-catenin 
signaling pathway, integrins, Notch transcription factors, 
prostaglandin E2, Cyclooxygenase-2, and hormones [9, 
12]. 
 During cancer progression, EMT appears to 
promote dissemination of cells from the tumor mass [13] 
and facilitate tissue invasion by regulating the production 
of matrix metalloproteases and altering cytoskeletal 
organization [14]. EMT plays an important role in OC 
metastasis. It was reported that EMT was induced by 
transforming growth factor-β (TGF-β), epidermal growth 
factor (EGF), hepatocyte growth factor (HGF) and 
endothelin-1 (ET-1) in OC cell lines [15]. Kajiyama and 
colleagues found that high level expression of Twist1 
is associated with the FIGO stage as well as positive 
peritoneal cytology and predicts poor clinical outcomes 
in patients with clear cell carcinoma (CCC) of the ovary, 
suggesting that Twist1 may play a critical role in the 
metastatic process of CCC of the ovary [16]. Similarly, 
by comparing 54 cases of OC and paracancerous tissues, 
it was found that up-regulation of Twist is correlated 
with OC metastasis [17]. In another study, analysis 
of 174 primary tumors and 34 metastases of OC by 
immunohistochemistry (IHC) demonstrated a reduced 
E-cadherin expression and an increased expression 
of Snail are significantly associated with peritoneal 
metastasis and both the progression-free survival (PFS) 
and OS in patients with OC [18]. Zeb1, an important 
transcriptional suppressor of EMT, was found to be 
positively correlated with migration ability in SKOV-3 and 
HO8910 EOC cell lines, and the down-regulation of Zeb1 
with short hairpin RNA (shRNA) in SKOV-3 cells could 
significantly decrease tumor growth in mice xenograft 
[19]. These data support the significant role of EMT in 
OC progression, indicating targeting EMT holds promise 
to prevent OC progression.
EMt in ovarian cancer chemoresistance
 Increasing evidence demonstrates that there is a 
close relationship between EMT and chemoresistance in 
OC. Treatment with chemotherapeutics in vitro can induce 
chemoresistance and EMT. It was reported that continuous 
exposure to increasing doses of paclitaxel induced 
chemoresistance as well as EMT, and enhanced metastasis 
potential in EOC cells (NOS-2, TAOV and SKOV-
3) [20]. Similarly, Latifi et al observed that cisplatin 
induced Twist1 expression in OVCA443 EOC cell line, 
with increased cell migration [21]. After treatment by 
carboplatin, the SKOV-3 EOC cells were demonstrated 
triggering both EMT and chemoresistance [22]. 
 EMT markers and transcription factors are in 
correlation with chemoresistance in OC. In one study, up-
regulation of EMT-related transcription factors Snail, Slug, 
Twist2 and Zeb2 in gene level and Snail, Slug, Vimentin 
in protein level was found in cisplatin resistant EOC cell 
line A2780-cis compared with cisplatin sensitive EOC cell 
line A2780 using gene expression and proteomic analysis, 
respectively [23]. Using 100 fresh advanced-stage ovarian 
serous carcinoma effusions, Davidson et al analyzed 10 
EMT and CSC protein markers including E-cadherin, 
N-cadherin, P-cadherin, Zeb1, HMGA2, Rab25, CD24, 
NCAM (CD56), Sox11 as well as Vimentin, and identified 
Vimentin and Zeb1 as markers of poor chemoresponse in 
metastatic serous ovarian carcinoma effusions [24]. It 
was also found that reversal of EMT by down-regulating 
EMT makers can restore the chemosensitivity in OC. 
For example, Haslehurst et al found that, by reducing 
expression of Snail and Slug, the mesenchymal phenotype 
was largely reduced and cells were re-sensitized to 
cisplatin [23]. These findings demonstrate EMT has a 
critical role in OC chemoresistance, and inhibiting or 
reversing EMT could be a good choice in the treatment 
of OC.
 The potential mechanisms of EMT in OC 
chemoresistance are still not fully uncovered. 
Accumulating evidence from preclinical and human tissue 
studies indicates that several important signaling pathways 
may contribute to OC chemoresistance via EMT, resulting 
in tumor metastasis and recurrence after chemotherapy. 
Different EMT-related signaling pathways associated 
with OC chemoresistance are summarized in Table 1. 
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In Kurrey’s study, both Snail and Slug were shown 
to impose acquisition of the CSC-like phenotype and 
chemoresistance in OC cells by overcoming p-53 mediated 
apoptosis [25]. Yue et al reported that hyperactive EGFR/
STAT3 signaling promoted EMT during OC cisplatin 
resistance development [26]. By studying the molecular 
profiles from 23 stage III-IV OC biopsies at primary 
surgery, it was found that the activation of EMT by the 
TGF-β pathway is a signature indicative of resistance to 
platinum-based chemotherapy [5]. In another study, it was 
found that Notch3 activation induces EMT and attenuates 
carboplatin-induced apoptosis which is associated with 
inhibition of carboplatin-induced ERK phosphorylation in 
OVCA429 cells [27], indicating that Notch3 is associated 
with OC carboplatin resistance.
 In addition to signaling pathways, microRNAs 
(miRNAs) also play a significant role in EMT in OC 
chemoresistance, among which miR-200 family is the 
most important one. The aberrant expression of miR-200 
family (miR-200a, miR-200b, miR-200c, miR-141 and 
miR-429) in OC and its involvement in EMT were well-
demonstrated [28], illustrating the importance of miR-200 
table 1: the EMt-related signaling pathways in oc chemoresistance 
Pathway Experiment approach EMt markers chemodrugs used in oc chemoresistance reference
p53 mediated 
apoptosis pathway in vitro cell lines Snail, Slug paclitaxel [25]
EGFR/Stat3 pathway
in vitro cell lines; in vivo 
animal models;  and 
human tissues 
Vimentin cisplatin [26]
TGF- β  pathway Human tissue Zeb1 carboplatin and taxol [5]
Notch3/ERK pathway in vitro cell line
E-cadherin, 
Snail, Slug, 
SMA
carboplatin [27]
Figure 1: Putative mechanisms of EMt in ovarian cancer chemoresistance and progression. EMT process plays an 
important role in tumor invasion, metastasis, recurrence and chemoresistance. This process is potentially regulated by different mechanisms, 
including EMT inducer signaling pathways, EMT transcription factors, dyregulation of miRNAs as well as several kinds of growth factors. 
In addition, MET may also happen during tumor progression in order to allow tumor growth and colonization, resulting in tumor settlement.
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family in OC chemoresistance through promoting EMT 
process. Using a well-characterized OC tissue achieve (n 
= 72), it was demonstrated that patients without complete 
response (CR) to paclitaxel-based chemotherapy had 
lower miR-200c levels than patients with CR, additionally, 
low miR-200 family (miR-200c, miR-141, and miR-
429) expression had a trend toward poor PFS [29]. In 
another study, by analyzing the differences between 
biopsies from primary surgery and second surgery for 
relapse after several lines of chemotherapy (SCR) of 23 
stage III-IV OC patients, the median expression levels 
of miR-200 family was observed to be down-regulated 
nearly two-fold in SCR group compared with those in 
primary surgery group, and the up-regulation of Zeb1 
parallels the turn-off of miR-200 [5]. In a recent study, 
it was shown that paclitaxel resistant OVCAR-3/CP and 
MES-OV/CP EOC cell lines displayed a strong EMT 
phenotype, with marked decreases in expression of miR-
200c and miR-141 in OVCAR-3/CP, and down-regulation 
of all five members of miR-200 family in MES-OV/CP 
[30]. Following inhibition of miR-200c and miR-141 in 
parental OVCAR-3 cells, EMT was triggered and rendered 
the cells resistant to paclitaxel and carboplatin, while the 
infection of paclitaxel resistant variants, OVCAR-3/TP 
cells with retroviral particles carrying the miR-200ab429 
and 200c141 clusters triggered a partial mesenchymal 
to epithelial transition, further indicating the important 
role of miR-200c and miR-141 in OC chemoresistance 
and EMT [30]. The putative mechanisms of EMT in OC 
chemoresistance are shown in Figure 1.
 All findings suggest that EMT is closely linked with 
OC metastasis, chemoresistance and progression, which is 
regulated by different signaling pathways and microRNAs, 
and that identification of main signaling pathways and new 
miRNA associated with EMT is undoubtedly an important 
step to develop new modalities to prevent metastatic, 
recurrent OC and improve the clinical outcomes of OC 
patients.
table 2: targeted therapy for reversing EMt in the treatment ovarian cancer chemoresistance
Approach for 
EMt targeting 
chemodrug 
used in 
combination
target Effect targeting site mechanism
Experiment 
type reference
Thiostrepton cisplatin FOXM1 Chemosensitivity↑, stemness↓
EMT-related marker 
(FOXM1)
in vitro,
 in vivo [36]
UO126 cisplatin ERK Chemosensitivity↑, migration↓
EMT-related ERK 
pathway
in vitro,
 in vivo [21]
S31-201 cisplatin Stat3 Chemosensitivity↑ EMT-related Jak-Stat3 pathway
in vitro, 
in vivo [26]
ZD1839 cisplatin EGFR Chemosensitivity↑ EMT-related EGFR pathway
in vitro,
 in vivo [26]
LY294002 paclitaxel PI3K Chemosensitivity↑ EMT-related PI3K pathway
in vitro, 
in vivo [31]
Zibotentan
cisplatin 
or taxol or 
paclitaxel
ETAR
Chemosensitivity↑,  
invasiveness↓
EMT-related 
ETAR/b/are-stin-1 
pathway
in vitro, 
in vivo [38]
SFRP5 expression 
vector
cisplatin 
or taxol or 
etoposide
SFRP5 Chemosensitivity↑ Epigenetic therapy in vitro, in vivo [32]
Trichostatin A cisplatin histone deacety-lase Chemosensitivity↑ Epigenetic therapy
in vitro,
 in vivo [33]
5-aza-CdR cisplatin
DNA 
methylt-
ransfer
-ase 
Chemosensitivity↑ Epigenetic therapy in vitro, in vivo [33]
miRNA-186 cisplatin Twist 1 Chemosensitivity↑ Epigenetic therapy in vitro, in vivo [34]
miRNA-506 cisplatin and olaparib
RAD51 and 
Snail1
Chemosensitivity↑, 
metastasis↓ Epigenetic therapy
in vitro, 
in vivo [35]
AuNPAs
(gold 
nanoparticle)
cisplatin N/A Chemosensiti-vity↑,metastasis↓ Targeted therapy
in vitro, 
in vivo [37]
notes: n/A: not available; ↑: increase; ↓: reduce 
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targeting EMt in oc treatment
 Due to serious side effects of chemotherapy, 
targeted therapy plays a very important role in the current 
OC treatment. Accumulating evidence indicates that 
targeting EMT is a new developing research area and holds 
promise for chemoresistant OC patients in the future. 
 Developing cancer cell signaling pathway 
treatment is an important area for EMT-targeting therapy. 
In OVCA433 EOC cell line and tumors collected from 
advanced-stage EOC patients, ERK2 signaling pathway 
was found to be critical to cisplatin-induced EMT and 
CSC phenotypes. It was reported that the ERK inhibitor 
U0126 could block cisplatin-induced ERK2 activation, 
and sensitize the residual cells to increase cell death in 
response to cisplatin in vitro and inhibit cisplatin-induced 
migration in zebrafish embryos in vivo [21]. Hyperactive 
EGFR and the Jak-Stat3 pathways were found to be 
the key mediators of the EMT process associated with 
cisplatin resistance in cisplatin resistant EOC cell lines, 
and the combination of ZD1839 (EGFR inhibitor) or 
S3I-201 (Stat3 inhibitor) with cisplatin could sensitize 
cisplatin-resistant EOC cells in vitro and intra-peritoneal 
mouse xenografts in vivo [26]. Du et al found that EMT 
was related to the paclitaxel resistant A2780/PTX EOC 
cells, and the application of the PI3K inhibitor LY294002 
could reverse the EMT phenotype and restore sensitivity 
to paclitaxel in A2780/PTX, indicating the therapeutic 
target of PI3K signaling pathway which is associated with 
EMT [31]. 
 Epigenetic aberrations, including DNA methylation, 
histone modifications, and miRNA dysregulation also 
contribute to the EMT in OC. Therefore, reversing 
these changes has significant benefits as alternatives to 
traditional cytotoxic therapy. For example, epigenetic 
silencing of SFRP5 was observed to lead to oncogenic 
activation of the Wnt pathway and contribute to OC 
chemoresistance through the Twist-mediated EMT and 
AKT2 signaling, and the overexpression of SFRP5 
inhibited EMT, down-regulated AKT2 and sensitized OC 
cells to chemotherapy, indicating the treatment promise 
of target reactivation of epigenetically silenced gene [32]. 
Trichostatin A, a histone deacetylase inhibitor or 5-aza-
CdR, a DNA methyltransferase inhibitor, in combination 
with low-dose cisplatin significantly inhibited spheroid 
formation and tumorigenicity via the suppression of EMT 
and pluripotency of OC cells, both in vitro and in vivo. 
Most importantly, both epigenetic modifiers increased 
the sensitivity of the highly chemoresistant EOC cell line 
HEY to cisplatin, suggesting their promising application 
in OC chemoresistance treatment [33]. 
 miRNAs have also shown their treatment promise 
in OC. Zhu et al demonstrated that miR-186 was detected 
to be associated with EMT and cisplatin-resistance 
in EOC cell lines (ACRP, C13* and OVCAR3/DDP) 
and human EOC tissues (cisplatin-sensitive tumors vs 
cisplatin-resistant tumors), and the introduction of miR-
186 to EOC cells led to reduction of Twist1 as well as 
EMT, and rendered the cells more sensitive to cisplatin in 
vitro and in vivo [34]. Similarly, it was reported that miR-
506 is associated with better therapy response and PFS 
and OS in EOC by analyzing The Cancer Genome Atlas 
(ACGA) (n = 486) and Bagnoli (n = 130) datasets [35]. As 
a result, miR-506 sensitizes EOC cells to chemotherapy 
and inhibits EMT-mediated metastasis. 
 In terms of the application of EMT marker 
targeting, Chiu et al illustrated that FOXM1 was a critical 
regulator of the EMT, stemness, and chemoresistance 
in EOC cells, and the combination of FOXM1 inhibitor 
thiostrepton and cisplatin inhibited the expression of 
EMT related markers (OCT4, Nanog, Notch-1) in 
chemoresistant A2780CP70 cells and growth of ovarian 
xenograft tumors in a subcutaneous (s.c) mouse model, 
indicating the promising application of EMT targeted 
therapy for future EOC treatment [36].
 Some other small molecular inhibitors have 
also demonstrated the ability to reverse EMT and 
potentially increase chemosensitivity in OC. Using a gold 
nanoparticles (AuNPs), Xiong et al reversed cisplatin-
induced chemoresistance by inhibiting EMT in vitro 
using EOC cell lines (A2780, OVCAR5, SKOV3-ip), and 
sensitized orthotopically implanted ovarian tumors to a 
low dose of cisplatin in vivo on athymic nude female mice 
[37]. Targeting EMT with different approaches in OC is 
shown in Table 2. 
 All findings support that targeting EMT is a bright 
research area to prevent OC chemoresistance and it is 
worthwhile developing combination approaches in the 
future to improve current modalities. However, we need 
to realize that although these agents can reverse OC 
chemoresistance for combination therapy, they have very 
broad activities or targeting signaling pathways that are not 
limited to the EMT targeting. Therefore, when choosing 
these agents for combination therapy, we should maximise 
their anti-EMT effects and avoid their side effects.
cscs In ovArIAn cAncEr 
chEMorEsIstAncE
csc models
 Although there exists a long-lasting debate 
regarding the origin of CSCs, it is widely accepted that 
tumors are composed of phenotypically and functionally 
heterogeneous cells and CSCs are only a small subset of 
tumors cells. The stochastic model, hierarchy model and 
the dedifferentiation model are the three major theories as 
to how CSCs arises.
 The earlier CSC model is a static one. According to 
stochastic model, tumor cells are biologically equivalent 
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but behave variably due to stochastic influences (intrinsic 
and extrinsic factors). The core of this theory is that 
behaviors of tumor cells cannot be predicted and every 
tumor cell is thought to have the potential to behave the 
activity of CSCs [39]. The hierarchy model, which is the 
most universal accepted hypothesis, supports that tumors 
consist of distinct cell classes with differing functional 
abilities and behaviors on the basis of different intrinsic 
characteristics. Based on this model, CSCs are the only 
subpopulation possessing self-renewal and giving rise 
to non-tumorigenic progenies that make up the bulk of 
tumor [39]. However, data emerging in the last couple 
of years has revised the model to a dynamic one, where 
the hierarchical feature of the CSCs turns out to be more 
transient than once thought. That is, new progenies acquire 
the ability of self-renewal through de-differentiation 
of progenitor cells, as well as reversal of terminally 
differentiated cells [40]. The implications of CSCs and 
their offspring gaining self-renewal suggest the necessity 
to evolve current cancer treatments to target both bulk 
terminal differentiated cells and those with self-renewal 
potential [41] . 
the putative csc markers in ovarian cancer
 Accumulating evidence indicates that CSCs have 
close relationship with OC progression, metastasis, 
therapeutic resistance and tumor recurrence. The 
concept of CSCs has opened new areas of research in 
carcinogenesis, but has more immediate translational 
potential of uncovering new treatment targets. 
 Ovarian CSCs (OCSCs) have been isolated 
from established OC cell lines, ascites, and primary 
and metastatic tumors [42-45]. They share several 
characteristics with normal stem cells, including the ability 
to form anchorage-independent spherical aggregates, 
express stem cell markers, undergo membrane efflux, form 
clones in culture and in addition, exhibit enhanced tumor-
forming ability [46]. A number of cell surface markers 
have proved useful for the isolation of subsets enriched 
for OCSCs including CD44, CD133, CD117, CD24, 
ALDH1A1 and EpCAM.
 CD44 is a cell-surface glycoprotein involved in 
cell-cell interactions, cell adhesion and migration. The 
multiple protein isoforms are encoded via a single gene by 
alternative splicing and are further modified by a range of 
post-translational modifications (PTMs) [47]. CD44 was 
well documented to be a common CSC marker in many 
cancers such as breast cancer, head and neck squamous 
cell carcinoma, pancreatic cancer, colon cancer, as well 
as OC, and proved to be correlated with therapeutic 
resistance. Zhang et al isolated and characterized ovarian 
cancer-initiating cells (OCICs) from primary ovarian 
tumors using CD44 and CD117 antibodies, which were 
fully capable of re-establishing their original tumor 
hierarchy in vivo, indicating that both CD44 and CD117 
positive cells are OCSCs (Zhang, Balch et al. 2008). 
Besides, they also found that CD44+/CD117+ cells had 
increased chemoresistance to taxane and platinum-based 
chemotherapy as well as the ability to self-propagate 
[42]. Similarly, Alvero and colleagues showed that CD44+ 
cells were enriched in the ascites of OC patients, and the 
isolated CD44+ cells in mouse xenograftes gave rise to 
tumors with both CD44+ and CD44- cells, suggesting that 
those CD44+ cells can differentiate and self-renew with the 
feature of cancer-initiating cells, in addition, CD44+ EOC 
cells were demonstrated to be more resistant to paclitaxel 
and carboplatin compared with CD44- cells.[48]. 
 CD117, also known as c-Kit or stem cell growth 
factor receptor, is a proto-oncogene encoded by the KIT 
gene. It is a type of tyrosine kinase receptor involved 
in cell signal transduction and has been shown to be 
involved in apoptosis, cell differentiation, proliferation, 
and cell adhesion [49]. CD117 was found to have high 
expression in OC cells [45]. Interestingly, using cancer 
cells isolated from human primary OC tissues and ascites, 
Luo and his colleagues demonstrated that CD117+ OC 
cells appeared to be highly tumorigenic than CD117- OC 
cells as it only took approximately 103 cells to be able 
to self-renew, differentiate, and regenerate tumor in 
mouse models, and CD117 expression was statistically 
correlated with resistance to conventional chemotherapy 
[50]. Another study also reported that the Wnt/β-catenin 
pathway which plays an important role in the development 
of chemoresistance is activated by CD117 in SKOV-3 
and HEYA8 EOC cell lines [51], further confirming the 
importance of this marker in OC chemoresistance. 
 CD133, a pentaspan membrane glycoprotein, has 
been identified as a CSC marker for various cancers [52]. 
In EOC, CD133 has emerged as one of the most promising 
CSC markers based on in vitro cell lines, in vivo animal 
xeongrafts and human primary tumor experiments. It was 
reported that CD133+ A2780, PEO1 EOC cells generate 
both CD133+ and CD133- daughter cells, exhibiting 
enhanced resistance to platinum-based therapy in vitro and 
sorted CD133+ OC cells from A2780 line formed more 
aggressive tumor xenografts at a lower inoculum than their 
CD133- progenies on BALB/cAnNCr-nu/nu mice [43]. 
Curley et also found that tumor-derived CD133+ cells from 
human primary OC tissues have an increased tumorigenic 
capacity and are capable of recapitulating the original 
heterogeneous tumor in NOD/SCID mice compared with 
CD133- cells [44]. 
 CD24, the cell surface protein, is highly expressed 
in many human cancers [53]. It was reported that CD24 
could be used as a CSC marker in nasopharyngeal 
carcinoma [53], pancreatic cancer [54] and OC [55]. Gao 
et al isolated cancer cells from human primary ovarian 
tumor specimens and identified a sub-population defined 
by CD24 phenotype. Their experiments demonstrated that, 
compared with CD24- cells, CD24+ cells possesses stem-
cell like characters with relative quiescence, self-renewal, 
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differentiation, chemoresistance in vitro, and a xenograft 
injection of 5000 CD24+ cells produced tumors in nude 
mice, while injection of an equal number of CD24- cells 
failed to do so [55]. Using a transgenic murine model of 
OC, Burgos-Ojeda et al recently found CD24+ OC cells 
were enriched for cancer-initiating cells, and CD24+ cells 
have increased tumor sphere-forming capacity and play 
a role in tumor migration and metastasis [56]. However, 
Ment et al reported that the CD44+/CD24- phenotype in 
OC cells demonstrate CSC-like properties of enhanced 
differentiation, invasion, and resistance to chemotherapy 
and correlation to clinical endpoints with increased risk of 
recurrence and shorter PFS duration in patients with OC 
[57]. Gunjal et al also found that CD24- cells, if expanded 
from a singly sorted cell, may give rise to cells containing 
all of the markers, including CD24 [58]. Based on these 
findings, CD24 cell surface marker in CSC phenotype 
fluctuates with tumor environment and cell expansion, 
suggesting that the role of CD24 in OCSC remains plastic 
and inconclusive, and further investigation is needed to 
elucidate its role.
 ALDH enzymes belongs to a family of 
evolutionarily conserved enzymes comprised of 19 
isoforms that are localized in the cytoplasm, mitochondria 
or nucleus. Generally, ALDHs are generated by a wide 
variety of metabolic processes and are responsible for 
oxidizing aldehydes to carboxylic acids [59]. ALDH was 
initially used to isolate CSCs in leukemia, based on the 
increased ALDH activity using the aldeflour assay [60]. 
Landen et al for the first time isolated putative CSCs 
in OC by high ALDH activity, and showed that high 
ALDH expression predicts poor outcome in OC patients 
[61]. Later on, Silva et al demonstrated that as few as 
11 enriched ALDH+CD133+ CSCs isolated from human 
ovarian tumors were sufficient to initiate tumors in mice 
and that the presence of ALDH+CD133+ cells in debulked 
primary tumor specimens correlated with reduced disease-
free survival (DFS) and OS in OC patients, indicating that 
both ALDH and CD133 can be used as a functionally 
significant set of markers to identify OCSCs [62]. Liu et 
al. recently demonstrated that elevated ALDH expression 
was associated with poor prognosis in OC patients using 
meta-analysis [63]. Similarly, Mizuno et al also found 
high ALDH1 expression levels in human OC tissues are 
related to advanced stage in clear cell carcinoma cases 
and ALDH1 expression significantly reduced PFS. They 
also found that ALDH+ CSCs might have increased 
Nrf2-induced antioxidant scavengers, which lower ROS 
level relevant to chemoresistance in ovarian clear cell 
carcinoma [64]. In another study, high level expression of 
Lgr5 and ALDH1 in primary EOC was found to correlate 
with advanced tumor stage and grade as well as poor 
prognosis of the patients [65]. These data suggest ALDH 
is an OCSC marker associated with EOC progression and 
chemoresistance.
 EpCAM (epithelial cell adhesion molecule), is a 
glycosylated, 30~40 kDa type I transmembrane protein, 
which was reported to be expressed on essentially all 
human adenocarcinoma, and is part of the signature of 
CICs in numerous solid tumors as well as normal stem 
cells [66]. EpCAM has been used as an important OCSC 
marker. Katia et al selected a CD44+/CD24+/EpCAM+/E-
cadherin- subpopulation of cells from EOC cells (SKOV-
3 and OVCAR-5) using flow cytometry, and found that 
this small population of cells (less than 1%) has increased 
colony formation and shorter tumor-free intervals on a 
mouse s.c xenograft model in vivo after limited dilution, 
showing initiating tumor cell properties, and is resistant 
to both doxorubicin and cispation therapies [67]. By 
evaluating the expression of EpCAM at both RNA and 
protein levels in 4 normal fresh-frozen ovaries and 96 EOC 
biopsies (50 primary ovarian carcinomas, 34 metastatic, 
and 12 recurrent ovarian tumors, respectively), Bellone 
et al. found that EpCAM was significantly expressed in 
EOC tissues compared to the normal ovary tissues, and 
metastatic/recurrent tumours were found to express higher 
levels of EpCAM than primary ovarian carcinomas. More 
interestingly, a high surface expression was also found in 
100% (5/5) of the chemoresistant ovarian carcinoma cell 
lines derived from OC patients studied by flow cytometry 
[68]. These results indicate that EpCAM has significantlly 
clinical significance for targeting chemoresistant recurrent 
OC.
 Using existing CSC makers to define OCSC is an 
important step to uncover OC chemoresistant mechanisms, 
find useful therapeutic targets and develop new treatment 
modalities to cure metastatic, recurrent OC. However, 
none of these current CSC markers are exclusively 
expressed by OC tissues, highlighting that it is imperative 
to use combinatorial makers or delineate more specific 
markers and techniques to detect OCSCs. 
 In addition to cell surface OCSC markers, side 
population (SP) cells also play an important role in 
identification of OCSCs. SP cells can be separated by 
using the fluorescent DNA-binding dye such as Vybrant® 
DyeCycleTM Violet [69], and Hoechst 33342 [70], 
depending on the expression of ATP-binding cassette 
transporters (ABC transporters), or the unique pattern 
of cell growth in specific cell culture medium for sphere 
formation [71]. The SP cells were normally demonstrated 
to be highly enriched for CSC markers and endowed 
with regenerative capacities. For instance, after several 
passages, purified sphere-forming cells were isolated and 
found to express various stem cell markers (stem cell 
factor, Notch-1, Nanog, ABCG2, and Oct-4)[72].
 The studies from different groups have identified 
and isolated SP of OC cells with typical “CSC phenotype” 
(ability to self-renew, developing tumors in very 
small numbers~100 cells, resistance to therapy) [42, 
55, 73-74]. In a systematic screen of 6 EOC cell lines, 
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Boesch et al demonstrated that the SP of EOC cells 
defines a heterogeneous compartment exhibiting CSC 
characteristics and the exact identity of the CSC is still 
disguised by the high complexity of the CSC-containing 
compartment, suggesting that further functional studies 
are needed to determine whether a single cellular subset 
can unambiguously be defined as CSC or whether 
multiple stem cell-like cells with different properties 
coexist [69]. Yasuda et al found that the use of SP and 
aldehyde dehydrogenese bright (ALDHBr) overlapping 
population is a promising approach to isolate highly 
purified CSCs/CICs from OC cells and demonstrated this 
population exhibited higher tumor-initiating ability than 
that of SP cells or ALDH Br cells alone, enabling initiation 
of tumor with as few as 100 cells and showing higher 
sphere-forming ability, cisplatin resistance, adipocyte 
differentiation ability and expression of SOX2 than those 
of SP/ALDHLow, MP (main population)/ALDHBr and 
MP/ALDHLow cells [75]. SP population was reported to 
be increased in paclitaxel-resistant OC cell lines (2008/
PX24, KF28TX, TU-OM-1 TX) but not increased in 
cisplatin-resistant cell lines (C13, KFr13, TU-OM-1 
CDDP), suggesting SP cells are specially associated 
with paclitaxel resistance [76]. Using Hoechst 33342 dye 
efflux, Szotek et al identified and characterized SP cells 
from two distinct genetically engineered mouse OC cell 
lines (MOVCAR7 and 4306) with the capacity for self-
renewal and production of heterologous non-SP progeny, 
and found that SP cells showed a higher tumor forming 
ability and chemoresistance than non-SP cells [70]. These 
results indicate SP population has an important role in OC 
chemoresistance.
 Due to the importance of CSCs and the limitation 
of the current techniques to effectively detect CSCs, 
some new approaches are required to separate SP cells 
possessing CSCs properties for an in-depth investigation. 
All putative OCSC markers, origin and tumorigenicity in 
mice are shown in Table 3.
Significance of CSCs in ovarian cancer 
chemoresistance
 The CSC theory has offered a potential explanation 
for the relapse and resistance that occur in many tumors 
including OC after therapy [77]. CSCs prossess the 
capability to recapitulate a heterogeneous tumor upon 
transplantation and may produce tumors through self-
renewal and differentiation into multiple cell types. These 
CSCs may provide a reservoir of cells that cause tumor 
recurrence after therapy [78]. CSCs embody the refractory 
nature observed among many cancers: very competent 
table 3: Putative ocsc markers and tumorigenicity
Marker cell source Minimum cell number required for tumorigenicity in mice reference
CD44
Primary human ovarian tumors 102 (CD44+/CD117+) [42]
Ascites from OC patients N/A [48]
CD117 Primary human ovarian tumors and ascites 10
3 (CD117+) [50]
CD133
A2780 cell line 103 (CD133+) [43]
Primary human ovarian tumors 104 (CD133+) [44]
CD24 Primary human tumors 5x103 (CD24+) [55]
ALDH A2780 cell line 103 (ALDH+/CD133-), 30 (ALDH+/CD133+) [62]
EpCAM SKOV-3, OVCAR-5 cell lines 10
2 (EpCAM+/CD24+/CD44+/ E-cadherin- 
from OVCAR-5) [67]
SP
(efflux Vybrant® 
DyeCycleTM Violet)
A2780, A2780V, B2/92, B16/92, 
B17/92, IGROV1 cell lines
mice receiving 104 SP cells
succumbed to the tumor burden significantly 
earlier than did the NSP controls
[69]
SP
(efflux Hoechst 33342)
MOVCAR7 and 4306 mouse 
OC cell lines
1.5x105 SP at 10 weeks,
7.5 x105 SP at 7 weeks (MOVCAR 7 cell 
line)
[70]
SP
(efflux Hoechst 33342)
PTX-resistant cell lines
(2008/PX24, KF28TX, 
KFr13TX, and TU-OM-1 TX)
N/A [76]
 SP/ALDHBr MCAS, HTBoA, OVCAR3,OVSAHO, HEC-1cell lines 10
2 [75]
Notes: N/A: not available; NSP: non side population; SP: side population; OC: ovarian cancer; PTX: paclitaxel
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initial tumor establishment, extremely aggressive 
metastatic nature, resistance to chemo- and radiotherapy, 
correlation with advanced disease and resistance to 
current therapies. Therefore, if CSCs survive after anti-
cancer treatment, recurrence and metastasis are expected. 
Thus, investigation of CSCs has been a hot spot of basic 
cancer research and is rapidly expanding into many related 
aspects of cancer research, including chemo-sensitization. 
 Meng and colleagues demonstrated that the 
increased numbers of CD44+ cells from OC cell lines 
(SKOV-3, TOV112D and ES2) and patient ascites 
samples increased chemoresistance, and that patient 
ascites samples with > 25% CD44+ cells had significantly 
decreased median PFS (6 month vs 18 month, P = 
0.01) as well as propensity to recur (83% vs 14%, P = 
0.003) [57]. Through comparison of chemoresistant and 
chemosensitive primary OC tissue samples, Bonneau et 
al found that CD44 expression on tumor cells appeared 
to correlate with OS and could be used as a predictor 
of chemoresistance [79]. Similarly, by comparing the 
paired primary, metastatic, recurrent OC tissues from 
26 individual patients, another study showed that both 
the metastatic and recurrent tissues expressed higher 
level of CD44 than the patient matched primary tumors, 
and a significant association was found between CD44 
expression and both the DFS and OS. In the following 
in vitro and in vivo experiments, they also observed the 
overexpression of CD44 in chemoresistant cell lines 
(SKOV-3TR, OVCAR-8TR), and the knockdown of CD44 
by shRNA could significantly increase the sensitivity of 
OC cells (OVCAR8) to paclitaxel [80]. 
 Zhang et al found associations between CD133+ and 
higher grade ovarian tumors, advanced stage disease, and 
decreased response to chemotherapy in 400 OC primary 
tissue samples, demonstrating that CD133+ tumors are 
associated with decreased OS and shorter disease free 
interval [81]. In a meta-analysis, high CD133 expression 
level was also found to correlate with advanced tumor 
stages and a worse prognosis (reduced 2-year survival) 
in patients with OC [81]. Using a functional enrichment 
strategy, Chau et al separated a SP of cells from SKOV-3 
and HEYA8 EOC cell lines and found that the SP cells 
showed high CD117 expression, and the inhibition of 
CD117 (c-Kit) with c-Kit knockdown or imatinib (a 
c-Kit kinase activity inhibitor) could significantly reduce 
resistance to chemotherapeutic drugs (cisplatin/paclitaxel). 
[51]. Based on the analysis of 64 primary high grade 
ovarian serous carcinoma and peritoneal metastasis, it was 
demonstrated that patients with high CD117 expression 
in tumor cells had significantly shorter DFS, high CD133 
expression was correlated with shorter DFS and OS, and 
CD133 was proved to be an independent prognostic factor 
in the high grade serous carcinomas [82]. It was reported 
that in 65 advanced stage OC patients, more than 20% 
of ALDH1A1+ cells were found to be correlated with 
decreased PFS [61]. Zhu et al reported that overexpression 
of CD24 in EOC was an independent indicator associated 
with a low survival rate, increased metastasis, and 
decreased survival time [83]. These data support OCSCs 
have clinical significance for patients’ survival and disease 
course.
 Increasing number of studies have demonstrated 
that CSCs may confer growth advantage and metastasis 
in chemoresistant ovarian tumors [43, 45]. Silva et al 
reported that isolated ALDH+CD133+ OCSC-like cells 
from human primary ovarian tumors showed increased 
chemoresistance compared to their parental cells and the 
presence of ALDH+CD133+ cells in debulked primary 
tumors correlated with reduced disease-free and OS 
in OC patients [62]. Cole et al observed that short-
term chemotherapy to EOC cell lines (SKOV-3 and 
OVCA429) resulted in the purification of a subpopulation 
of cells overexpressing CSC-related markers (CD117, 
CD133, OCT4 and Nanog), and those CSC-like cells 
exhibited increased chemoresistance [84]. Abubaker 
et al also demonstrated that the chemotherapy-treated 
residual ovarian tumors were enriched in cells with 
CSC phenotypes on mice xenograft with HEY cells 
injection while the cells lacking these characteristics were 
eliminated both in vitro and in vivo [85]. We have recently 
found increased CSC phenotypes (CD44v6, CD117, 
CD105, Snail and ALDH1) and colony formation ability 
in a chemoresistant EOC cell line A2780-cis compared to 
their parental cell line A2780 (Figure 2). All these results 
suggest that chemoresistance has a close relationship with 
CSCs in OC, and the existence of CSCs may be the source 
of chemoresistance and recurrence.
the potential mechanisms of cscs in ovarian 
cancer chemoresistance
The mechanism of CSCs in OC chemoresistance 
and recurrence is complex and not fully understood. It is 
possible that decreased chemotherapy responsiveness of 
CSCs may be partly due to the slow proliferation rate, 
cell cycle arrest, the high expression of ATP transporters, 
efficient DNA protection and repair mechanisms, the 
activation of some CSC-related signaling pathways, 
inactivation of cell death pathways, and the inherent 
epigenetic aberrations. The putative mechanisms of CSC 
in OC chemoresistance are shown in Figure 3.
 It was reported that conventional chemotherapeutic 
treatment, which usually targets fast-dividing cells and 
acts in a cell-cycle specific manner, entitles CSCs the 
survival advantage because of their slow proliferation 
rate [86]. Gao et al found that CD24+ CSC cells were 
relatively quiescent and enriched at the S phase, leading 
to the chemotherapeutic resistance to cisplatin treatment 
compared with CD24- OC cells from human ovarian tumor 
specimens [55]. Abubaker et al demonstrated that a short-
term single exposure of chemotherapy induced surviving 
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OC cells with a CSC-like profile which was independent of 
the type of chemotherapy and the associated cytotoxicity 
[87].
 CSCs are known to possess highly elaborated efflux 
systems for cytotoxic agents, of which ABC family of 
membrane transporters are the most important ones. In 
return, there is strong collective evidence that increased 
expression and the activity of ABC family of membrane 
transporters, especially ABCG2, also correlates with 
cancer stem-like phenotype [88]. Ricci et al demonstrated 
that higher levels of ABCG2 efflux pump in OCSC-like 
cells were linked with increased resistance to taxol and 
VP16 therapy in OC cells which were obtained from 
primary ovarian carcinoma samples [89]. It was reported 
that Wnt/β-catenin-ABCG2 signaling pathway was 
activated and enhanced chemoresistance was observed 
in OCSCs, and β-catenin small interfering RNA (siRNA) 
reversed the drug sensitivity of OCSCs significantly 
[51]. Notch-1 and Nanog were also found to be co-
upregulated with ABCG2 when ovarian tumour initiating 
cells were cultured under stem cell-selective conditions, 
accompanied by enhanced chemoresistance to the OC 
chemotherapeutics [42].
 SP is also found to be related to OC chemoresistance 
via ABCG2. Kruger et al. demonstrated that SP cells from 
two murine carcinoma cell lines exhibited up-regulation 
of ABCG2 and stem cell markers Wnt-1 and Sca-1, 
increased resistance to chemotherapy, increased efflux of 
chemotherapeutic agents and increased ability to generate 
tumors in vivo [90]. 
 Moreover, up-regulated DNA protection and repair 
and inactivation of apoptosis may also be responsible for 
chemoresistance in OCSCs. Srivastava et al reported that 
an elevated expression of DNA polymerase η (Pol η) was 
observed in OCSCs isolated from both OC cell lines and 
primary tumors, and down-regulation of Pol η enhanced 
the cisplatin-induced apoptosis in CSCs both in vivo and 
in vitro [91], indicating that CSCs may have intrinsically 
enhanced translation DNA synthesis. On the other hand, 
a study demonstrated that p53 protein aggregation was 
associated with the inactivation of the p53-mediated 
apoptosis and platinum resistance in OC cells with CSC 
properties [92]. 
 In summary, there are many mechanisms involved 
in the OCSC-associated chemoresistance. Research 
efforts should be put in uncovering these mechanisms in 
the future in order to pave the way for OCSCs targeting 
therapy. 
Figure 2: Increased csc phenotype in Eoc-cis resistant cells compared with Eoc-control cells. A. Representative 
immunofluorescence images are shown for increased expression of CSC related markers (CD44v6, CD117, CD105, Snail and ALDH1) 
in A2780-cis resistant cells compared with A2780-control cells. Nuclei were stained with PI. Magnification: all images x 600. b. Western 
blotting results were consistent with immunofluorescence staining results. β-actin was used as a loading control. c. Increased clone forming 
ability was found in A2780-cis resistant cells compared with A2780 cells (P < 0.05). d. Typical images for colony growth in A2780-cis and 
A2780 cells. The results were from 3 independent experiments (n = 3).
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targeting cscs for oc treatment
 CSCs are implicated in cancer metastasis, 
recurrence, and therapeutic resistance. Targeting CSCs 
may possess many advantages by eradicating the root of 
tumor and managing their malignant behaviors. However, 
the data related with effective targeting strategies for CSCs 
are still limited until now. The current CSC targeting 
therapy in OC are mainly focused on the employment 
of OCSCs markers and the signaling pathways related to 
CSCs.
 Imatinib (Gleevec), a clinical drug that blocks 
Abelson cytoplasmic tyrosine kinase (ABL), CD177, 
and PDGFR, demonstrated its inhibition potency on 
OCSCs. In this study, the combination of imatinib with 
cisplatin/paclitaxel showed higher efficiency against 
the regeneration of drug-resistant OCSCs compared to 
imatinib or cisplatin/paclitaxel alone [51], indicating the 
table 4: targeting csc surface markers or csc-associated signaling pathways in ovarian cancer treatment
target Inhibitor reference
CD117 Imatinib [51]
CD133 dCD133KDEL [97]
PI3K/mTOR pathway VS-5584 [98]
JAK2/STAT3 pathway Ibrutinib [99]
JAK2/STAT3 pathway CYT387 [85]
Notch pathway GSI [100]
DNA methytransferace SGI-110 [101]
Figure 3: Putative mechanisms of cscs in oc chemoresistance. Ovarian cancer stem cells (OCSC) can be enriched after 
chemotherapy. The OCSCs may be related with several mechanisms including cell cycle arrest, increased DNA protection and repair 
enzyme system, inherent epigenetic aberration, the activation of some cell signaling pathways related to cell survival, inactivation of some 
cell signaling pathway correlated with cell death, as well as the high ATP binding cassette drug transporter system. These mechanisms 
contribute to ovarian cancer invasion, metastasis, recurrence and chemoresistance. EMT: epithelial mesenchymal transition.
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potential use of imatinib in the OCSCs target therapy 
for OC. However, in a phase II clinical trial, using a 400 
mg dose of imatinib had no significant effect on PFS in 
recurrent EOC [93, 94]. In another phase II clinical trial, 
at a higher dose of 600 mg imatinib, no clinical response 
was seen [95]. In platinum-resistant, recurrent EOC and 
with tumors that were positive for CD177 and PDGFR, no 
response rate was found with a 400 mg dose of imatinib 
in a phase II clinical trial [96]. Overall, the response rate 
of Imatinib has been very modest in clinical studies. 
Skubitz et al reported that targeting CD133 directly with 
a dCD133KDELa monoclonal antibody (MAb) that 
recognizes a non-glycosylated region of CD133, could 
successfully inhibit tumor growth and progression in OC 
mouse model [97], further providing the possibility of 
applying OCSC markers for future treatment.
 In addition, some signaling pathway inhibitors 
preferentially targeting CSCs are also useful in reversing 
chemoresistance. VS-5584, a dual inhibitor of mTORC1/2 
and class I PI3-Kinase, was reported to be up to 30-fold 
more potent in inhibiting the proliferation and survival 
of CSCs compared with non-CSC in OC and other 
solid tumor cells, and most importantly, VS-5584 was 
also able to significantly repress tumor regrowth after 
chemotherapy in an immunodeficient OC mouse model 
[98]. In another study, using OC cell line HEY, Abubaker 
et al demonstrated that inhibition of the JAK2/STAT3 
pathway by CYT387 suppressed the ‘stemness’ profile in 
chemotherapy-treated residual OC cells in vitro and animal 
xenograft models in vivo, leading to a reduced tumor 
burden [85]. Ibrutinib, a novel Bruton’s tyrosine kinase 
(Btk) inhibitor, was found to be able to significantly reduce 
the expression of JAK2/STAT3 pathway which in turn 
suppressed the survival of cancer cells through Sox-2 and 
BCL-XL genes and restored chemosensitivity in cisplatin-
resistant OC spheroids [99]. Furthermore, it was also 
reported that γ-secretase inhibitor GSI a Notch pathway 
inhibitor, was able to deplete CSCs and increase ovarian 
tumor sensitivity to platinum, and the combination of 
cisplatin and GSI was shown to effectively eliminate both 
CSCs and the bulk of tumor cells by enhancing the DNA-
damage response, G2/M cell-cycle arrest, and apoptosis 
[100]. We have recently demonstrated the activation of 
the PI3K/Akt/mTOR signaling pathway is associated with 
EMT and CSCs in chemoresistant EOC cell lines and 
combination of cisplatin and a dual PI3K/mTOR inhibitor 
(BEZ235) could increase chemosensitivity (unpublished 
observation), suggesting the PI3K/Akt/mTOR pathway 
plays an important role in EOC chemoresistance.
 Some emerging novel strategies have also 
demonstrated anti-CSC effects for improving OC 
chemoresistance. Donahoe et al demonstrated that 
mullerian inhibiting substance (MIS mimetic SP600125) 
preferentially inhibited chemotherapy-enriched CSC-
like cells in human EOC cell lines including OVCAR-5, 
IGROV-1 and SKOV-3 and provided a new treatment 
paradigm [73]. SGI-110, a new DNA methytransferace 
inhibitor, was found to reduce stem cell property of 
OC in a low dose through inducing re-expression of 
differentiation-associated genes HOXA10, therefore 
decreasing tumor initiating capacity and re-sensitizing 
CSCs to platinum. Moreover, the maintenance treatment 
with SGI-110 after carboplatin was also shown to inhibit 
CSC growth and decrease tumor progression in animal 
models in vivo [101]. Wang et al also demonstrated a low-
dose SGI-110 reduced the stem-like properties of ALDH+ 
EOC cells, including their tumor-initiating capacity, 
resensitized these OCSCs to platinum, and induced re-
expression of a differentiation-associated gene in mRNA 
level (HOXA10 mRNA ) [101].
 Wu et al recently reported that solanum incanum 
extract (SR-T100), containing the active ingredient 
solamargine, can down-regulate the expression of stem 
cell markers, including ALDH1, Notch1, and FoxM1, 
and reduce sphere formation in OC cells, increase the 
sensitivity of chemoresistant OC cells (A2780CP70) to 
cisplatin and paclitaxel in vitro. Furthermore, combination 
treatment using cisplatin and SR-T100 was more effective 
in inhibiting the tumor growth of A2780CP70 cells in 
mouse xenografts than either therapeutic alone, suggesting 
SR-T100 may have potential against chemoresistant OC 
cells [102]. Our group have developed aptamer-guided 
therapies such as aptamer-CD133 and aptamer-EpCAM 
conjugates for cancer treatments in preclinical studies and 
demonstrated low cytotoxicity, great binding affinity and 
penetration ability, and high efficacy for CSC targeting 
[103-104]. Aptamer-CD133 and aptamer-EpCAM hold 
promise for targeting OCSCs in the future research. 
Different inhibitors for OCSC-targeted therapy are shown 
in Table 4.
CSC markers are very dynamic and plastic during 
cancer progression. CSC phenotypes are regulated 
by tumor microenvironment. When designing a CSC 
targeting therapy, the CSC plasticity should be taken 
into consideration. It is important to determine the CSC 
expression at different stages of cancer. In addition, 
targeting several CSC markers may achieve a better 
clinical result than only targeting one CSC marker.
conclusIons And FuturE 
dIrEctIons
 Chemotherapy remains an important modality for 
advanced OC treatment with ongoing efforts towards 
designing new treatment modalities and techniques, which 
continue to improve the survival and quality of life in OC 
patients. However, chemoresistance and tumor recurrence 
are the major challenges for the current treatment failure. 
It is increasingly clear that EMT and CSCs play important 
roles in OC metastasis and progression and are related 
with chemoresistance, and targeting EMT and CSCs or 
their corresponding pathways by gene therapy, antisense 
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therapy, specific inhibitor, aptamer-guided therapy or 
other methods may enhance the chemosensitivity of OC. 
The recent advances in EMT and CSCs have unlocked a 
new avenue for chemosensitivity research. Elucidating 
the role of EMT and CSCs in the cancer cells’ response 
to chemotherapy will enhance our understanding of OC 
recurrence after chemodrug treatment, and may direct 
research towards novel and specific chemosensitizers 
that target EMT or CSCs. We expect that there will be 
increased understanding of the intrinsic and extrinsic 
factors that control the plasticity and maintenance of 
the EMT/CSC state (e.g. expression factors, miRNA 
expression, PTMs of molecules that control stem cell fate 
and niche factors that control stem cell renewal) in OC 
research.
 Since EMT and CSCs have both been implicated 
in tumourigenesis and chemoresistance, it is critical to 
examine both populations and determine their phenotypic 
expression in human OC recurrent tissues in order to 
develop strategies to target these populations using 
targeting therapy. Therefore, further evaluation of EMT/
CSC markers in OC tissues and investigation on how these 
cells can be targeted by novel treatment modalities might 
lead to more effective eradication of OC relapse. 
 EMT and CSC markers could be also used as 
important biomarkers for chemotherapy response and 
prognosis. If these biomarkers for predicting the treatment 
response of individual OC patient and potential targets for 
chemosensitization are further validated, it will achieve 
a more favorable therapeutic ratio in clinics. In addition, 
future personalized medicine for OC therapy will be 
developed from EMT and CSC research. 
 Studying the mechanisms of OC chemoresistance 
and metastasis is important for novel therapies. 
Chemoresistant mouse models or other contemporary 
models such as patients-derived xenografts (PDXs) or 
explanted human tissues from chemoresistant OC patients 
should be considered for new drug screening and testing. 
Combination of chemotherapy with novel agents targeting 
EMT/CSCs for improvement of chemosensitivity has 
demonstrated promise in preclinical studies on OC cell 
lines and animal models. However, only very limited 
data could be found in Phase I trials. These combination 
approaches should be further explored in clinical trials to 
validate their clinical effects in OC therapy.
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